DE69021128D1 - Interleukin-1-Inhibitor. - Google Patents

Interleukin-1-Inhibitor.

Info

Publication number
DE69021128D1
DE69021128D1 DE69021128T DE69021128T DE69021128D1 DE 69021128 D1 DE69021128 D1 DE 69021128D1 DE 69021128 T DE69021128 T DE 69021128T DE 69021128 T DE69021128 T DE 69021128T DE 69021128 D1 DE69021128 D1 DE 69021128D1
Authority
DE
Germany
Prior art keywords
protein
interleukin
inhibitor
directed
immunosuppression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69021128T
Other languages
English (en)
Other versions
DE69021128T2 (de
Inventor
Avi Treves
Vivian Barak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hadassah Medical Organization
Original Assignee
Hadassah Medical Organization
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hadassah Medical Organization filed Critical Hadassah Medical Organization
Application granted granted Critical
Publication of DE69021128D1 publication Critical patent/DE69021128D1/de
Publication of DE69021128T2 publication Critical patent/DE69021128T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69021128T 1989-05-19 1990-05-21 Interleukin-1-Inhibitor. Expired - Fee Related DE69021128T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35433089A 1989-05-19 1989-05-19
US50899990A 1990-04-12 1990-04-12
US52527490A 1990-05-17 1990-05-17

Publications (2)

Publication Number Publication Date
DE69021128D1 true DE69021128D1 (de) 1995-08-31
DE69021128T2 DE69021128T2 (de) 1996-02-29

Family

ID=27408176

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69021128T Expired - Fee Related DE69021128T2 (de) 1989-05-19 1990-05-21 Interleukin-1-Inhibitor.

Country Status (5)

Country Link
EP (1) EP0398817B1 (de)
JP (1) JP2863265B2 (de)
AT (1) ATE125571T1 (de)
CA (1) CA2017315C (de)
DE (1) DE69021128T2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6159460A (en) * 1988-05-27 2000-12-12 Amgen Inc. Method for treating interleukin-1 mediated diseases
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
US6858409B1 (en) 1988-05-27 2005-02-22 Amgen Inc. Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors
AU649245B2 (en) * 1990-04-02 1994-05-19 Amgen, Inc. Methods for treating interleukin-1 mediated diseases
DE4106570A1 (de) * 1991-03-01 1992-09-03 Max Planck Gesellschaft Neue inhibitoren der endothelzell-proliferation
NZ310561A (en) * 1995-09-13 1999-07-29 Takeda Chemical Industries Ltd Immunosuppressant of the aromatic variety based upon the quinoline family
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
CA2454824A1 (en) * 2001-07-25 2003-02-06 Nuvelo, Inc. Treatment of immune disorders and b cell disorders

Also Published As

Publication number Publication date
DE69021128T2 (de) 1996-02-29
ATE125571T1 (de) 1995-08-15
CA2017315A1 (en) 1990-11-19
JP2863265B2 (ja) 1999-03-03
EP0398817B1 (de) 1995-07-26
JPH03128397A (ja) 1991-05-31
EP0398817A1 (de) 1990-11-22
CA2017315C (en) 2000-07-18

Similar Documents

Publication Publication Date Title
CY1107495T1 (el) Χρηση παραγωγων τετρακυκλινης για να αυξανεται παραγωγη ιντepλευκινης-10
MX9200675A (es) Derivados de 2,4-diaminoquinazolinas para mejorar la actividad antitumoral.
ES2074867T3 (es) Derivados de quinazolina para potenciar la actividad antitumoral.
NZ335981A (en) Ketobenzamides as calpain inhibitors
DK0398327T4 (da) Tumornekrosefaktor-bindende protein, dets oprensning og antistoffer dertil
BG91270A (bg) Антивирусно и антибактериално средство и метод за използването му
ES2196082T3 (es) Analagos del factor de crecimiento de queratinocitos.
ES2151607T3 (es) Factor 12 de crecimiento y de diferenciacion.
IT8848329A0 (it) Trattamento batterico di conservazione della qualita' del fieno tramite aggiunta di microorganismi del genere bacillus
ATE206708T1 (de) Benzimidazolonderivate mit zentraler dopaminerger aktivität
ATE125571T1 (de) Interleukin-1-inhibitor.
ES2063060T3 (es) Benzamida contra enfermedades cognoscitivas.
PT775118E (pt) Derivados de benzimidazole com actividade dopaminergica
ES2068714T3 (es) Derivados de pirimidina para aumentar la actividad antitumoral.
ES2149952T3 (es) L-arginina y analogos como inhibidores de la agregacion de trombocitos.
EP0373540A3 (de) Verfahren zur Reinigung des Fibroblast-Wachstumsfaktor-Proteins
MY107235A (en) Use of tenidap to inhibit activation of collagenase and to inhibit the activity of myeloperoxidase.
IT8748663A0 (it) N-alchilammidi della dl e l(-)carni tina dotate di attivita'antibatteri ca,procedimento per la loro preparazione e composizioni farmaceutiche e cosmetiche che le contengono
ES2070134T3 (es) Inhibidores de lisil oxidasa.
CA2099497A1 (en) Peptides with anticoagulant activity
EP0248217A3 (en) Treatment of tumors with autologous lak cells, interleukin-2 and an ornithine decarboxylase inhibitor
RU94024337A (ru) Антиметастатическое средство
ES2114170T3 (es) Peptidos con actividad organo-protectora, su procedimiento de preparacion y su utilizacion en la terapia.
IT1234939B (it) Procedimento per la riduzione del contenuto di impurezze nella ghisa
RU92012316A (ru) Способ иммунотерапии раковых больных

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee